What is Blueprint Genetics?
Headquartered in Helsinki and Seattle, Blueprint Genetics operates at the intersection of biotechnology and clinical medicine. The company specializes in high-quality genetic testing, focusing specifically on rare inherited diseases. By leveraging advanced sequencing technologies and a robust bioinformatics pipeline, the firm provides clinicians with actionable insights that facilitate precision medicine. Its market position is defined by a commitment to diagnostic accuracy and a scalable service model that supports healthcare providers worldwide in navigating complex genetic landscapes.
How much funding has Blueprint Genetics raised?
Blueprint Genetics has raised a total of $26.2M across 3 funding rounds:
Unspecified
$3.9M
Other Financing Round
$6.3M
Private Equity
$16M
Unspecified (2014): $3.9M, investors not publicly disclosed
Other Financing Round (2016): $6.3M led by Inventure and Pontos Group
Private Equity (2017): $16M supported by Pontos Group, Creathor Venture, and Mtip
Key Investors in Blueprint Genetics
Pontos Group
Pontos Group is a long-term investment firm focused on private equity and real estate investments, aiming to double the value of its portfolio every decade through sustainable and holistic development.
Creathor Venture
Creathor Ventures invests in technology-oriented companies that drive the personalization and digitalization of healthcare, managing a fund volume exceeding 230 million euros.
Mtip
MTIP is a Swiss growth and buyout firm that specializes in acquiring and investing in profitable, high-growth healthcare software companies with recurring revenue models.
What's next for Blueprint Genetics?
Following the latest major strategic investment, Blueprint Genetics is well-positioned to accelerate its operational expansion and deepen its technological moat. The current lifecycle stage suggests a transition toward broader market penetration and the potential for further integration into international healthcare systems. Future growth will likely focus on enhancing the throughput of its diagnostic platforms and expanding its portfolio of genetic panels. By maintaining a focus on high-growth healthcare software and diagnostic innovation, the company is poised to remain a critical partner for medical institutions seeking to improve patient outcomes through genomic data.
See full Blueprint Genetics company page
